专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06696956B1 Emergency dispatching system 失效
标题翻译：紧急调度系统
公开(公告)号：US06696956B1
公开(公告)日：2004-02-24
申请号：US09979675
申请日：2001-11-06
申请人： Junji Uchida , Kyoko Uchida
发明人： Junji Uchida , Kyoko Uchida
IPC分类号： G08B2300
CPC分类号： G08B21/0423 , G08B21/043 , G08B21/0469 , G08B21/0484 , G08B21/0492 , G08B25/016 , H04M11/04
摘要： An emergency dispatching system which can reduce the occurrence of false reports, reliably send the first report to relatives or the like in an emergency, and automatically detect even the occurrence of an internal danger. Emergency dispatching system 10 comprises a communication device 12 for a monitored person, a sensor 14 for sensing the vital reaction or the like of the monitored person, contact address storage means 18 where a telephone number to contact in case of emergency is stored, message storage means 22 where a message to be sent in case of emergency is stored, safety judging means 16 for judging the safety of the monitored person based on the output of the sensor 14, dispatch notifying means 28 for warning the monitored person of the emergency when it is assumed by the safety judging means 16 that an emergency has occurred, automatic dialing means 20 for generating a dialing signal and outputting it to the communication device 12 in case where a safety confirmation input is not detected within a certain time since warning, and message dispatching means 26 for dispatching the message to a communication device 38 at a contact address after establishment of a communication line between the communication device 12 and the communication device 38.
摘要翻译：可以减少虚假报告发生的紧急调度系统，可靠地将紧急情况下的第一次报告发送给亲戚等，即使发生内部危险也自动检测到。紧急调度系统10包括用于被监视人的通信设备12，用于感测被监视人的重要反应等的传感器14，存储紧急情况下接触的电话号码的联系地址存储装置18，消息存储存储紧急情况下要发送的消息的装置22，用于基于传感器14的输出来判断被监视人的安全性的安全判断装置16，当发生紧急情况时监视到的人的警告的调度通知装置28 由安全判定装置16假设发生紧急情况，用于产生拨号信号的自动拨号装置20，并且在警告后的一定时间内没有检测到安全确认输入的情况下将其输出到通信装置12，以及消息调度装置26，用于在建立通信线路之间的通信线路的联系地址处将消息发送到通信设备38 单元装置12和通信装置38。

2. 发明申请

US20060116345A1 Antitumor effect potentiator and antitumor agent 有权
标题翻译：抗肿瘤效果增强剂和抗肿瘤剂
公开(公告)号：US20060116345A1
公开(公告)日：2006-06-01
申请号：US10548655
申请日：2004-03-11
申请人： Junji Uchida , Koyo Shudo
发明人： Junji Uchida , Koyo Shudo
IPC分类号： A61K31/7072 , A61K31/513
CPC分类号： A61K31/53 , A61K31/44 , A61K31/513 , A61K31/519 , C07D239/553
摘要： The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect, the antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing an antitumor effect; an antitumor agent comprising, as active ingredients, tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, oteracil potassium in an amount effective for inhibiting a side effect, and at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing an antitumor effect; a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent.
摘要翻译：本发明提供了一种抗肿瘤效果增强剂，其用于增强抗肿瘤活性，其包含治疗有效量的替加氟，具有提高抗肿瘤作用的量的吉莫斯特，以及有效抑制副作用的量的奥氮平钾，抗肿瘤剂所述增效剂包含选自由亚叶酸及其药理学上可接受的盐组成的组中的至少一种，其量为有效提高抗肿瘤效果的量; 一种抗肿瘤剂，其包含作为活性成分的治疗有效量的替加氟，具有提高抗肿瘤效果的量的吉非麦酸，有效抑制副作用的量的奥氮平钾，以及选自以下的至少一种：亚叶酸及其药理学上可接受的盐，其量可以有效提高抗肿瘤效果; 一种增强抗肿瘤剂抗肿瘤作用的方法，包括向患者施用上述抗肿瘤作用增强剂的步骤; 以及一种癌症治疗方法，包括向患者施用上述抗肿瘤剂的步骤。

3. 发明申请

US20140227706A1 Method for assessing progression of clinical state of malignant neoplasm by quantitative detection of DNA in blood 审中-公开
标题翻译：通过定量检测血液中的DNA来评估恶性肿瘤临床状态进展的方法
公开(公告)号：US20140227706A1
公开(公告)日：2014-08-14
申请号：US14118098
申请日：2012-05-16
申请人： Kikuya Kato , Fumio Imamura , Kazuya Taniguchi , Toru Kumagai , Junji Uchida , Kazumi Nishino
发明人： Kikuya Kato , Fumio Imamura , Kazuya Taniguchi , Toru Kumagai , Junji Uchida , Kazumi Nishino
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6881 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156
摘要： The object of the invention is to provide a method for quantitatively assessing the degree of progression of a malignant neoplasm in a patient who has been medicated. Provided is a method for assessing the progression of the clinical state of a malignant neoplasm in a subject who has been administered with a medicine for treating the malignant neoplasm, the method being characterized by comprising: (1) a step of determining the ratio of DNA molecules having an activation mutation that serves as an activation marker for the medicine to DNA molecules having a normal marker gene in DNA in the blood from the subject; (2) a step of determining the ratio of DNA molecules having a resistance mutation that serves as a resistance marker for the medicine to DNA molecules having a normal marker gene in the DNA in the blood from the subject; and (3) a step of comparing a value obtained in the step (2) with a value obtained in the step (1) to thereby assess whether or not the malignant neoplasm in the subject has acquired resistance to the treatment with the medicine.
摘要翻译：本发明的目的是提供一种用于定量评价已被给药的患者中的恶性肿瘤的进展程度的方法。本发明提供了一种用于评估已经给予恶性肿瘤治疗药物的受试者的恶性肿瘤的临床状态进展的方法，其特征在于包括：（1）测定DNA比例的步骤具有激活突变的分子，其用作药物的活化标记物，其具有来自受试者的血液中DNA中具有正常标记基因的DNA分子; （2）确定作为药物抗性标记的抗性突变的DNA分子与来自受试者的血液中的DNA中具有正常标记基因的DNA分子的比例的步骤; 和（3）将步骤（2）中获得的值与步骤（1）中获得的值进行比较的步骤，从而评估受试者的恶性肿瘤是否具有药物治疗的抵抗力。

4. 发明申请

US20090136516A1 Cd-20 specific antibodies and methods of employing same 有权
标题翻译： Cd-20特异性抗体及其使用方法
公开(公告)号：US20090136516A1
公开(公告)日：2009-05-28
申请号：US10556104
申请日：2004-05-07
申请人： Thomas F. Tedder , Junji Uchida , Yasuhito Hamaguchi , Jonathan C. Poe
发明人： Thomas F. Tedder , Junji Uchida , Yasuhito Hamaguchi , Jonathan C. Poe
IPC分类号： A61K39/395 , C07K16/28 , C12N5/06 , A61P37/02
CPC分类号： C07K16/2887 , A61K39/39558 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/732
摘要： The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.
摘要翻译：本发明提供了特异性结合CD20的单克隆抗体及其抗原结合片段，以及包含其的药物组合物。本发明还提供了使用单克隆抗体，抗原结合片段和药物组合物的方法，例如在消耗B细胞或治疗B细胞病症的方法中。还提供了用于产生单克隆抗体的细胞，核酸和方法。

5. 发明授权

US5420117A 5-substituted uridine derivatives 失效
标题翻译： 5-取代的尿苷衍生物
公开(公告)号：US5420117A
公开(公告)日：1995-05-30
申请号：US963250
申请日：1992-10-19
申请人： Tadafumi Terada , Katsuhiko Fujimoto , Junichi Yamashita , Mitsugi Yasumoto , Setsuo Takeda , Junji Uchida , Konstanty Wierzba , Yuji Yamada
发明人： Tadafumi Terada , Katsuhiko Fujimoto , Junichi Yamashita , Mitsugi Yasumoto , Setsuo Takeda , Junji Uchida , Konstanty Wierzba , Yuji Yamada
IPC分类号： C07H19/06 , C07H23/00 , A61K31/505
CPC分类号： C07H23/00 , C07H19/06
摘要： This invention provides a 5-substituted uridine derivative of the formula ##STR1## wherein X is F or CF.sub.3, R.sub.1 and R.sub.2 each represent a group --OSi--(R.sub.4)(R.sub.5)(R.sub.6) (wherein R.sub.4, R.sub.5 and R.sub.6 represent C.sub.1 -C.sub.10 alkyl or the like), OH, aminoacyloxy group wherein the amino group may be substituted with lower alkyl group or carboxylalkylcarbonyloxy group, R.sub.3 is a group --OSi(R.sub.4)(R.sub.5)(R.sub.6), H, OH, aminoacyloxy group wherein the amino group may be substituted with lower alkyl group, or carboxylalkylcarbonyloxy group, and at least one of R.sub.1, R.sub.2 and R.sub.3 is a group --OSi--(R.sub.4)(R.sub.5)(R.sub.6), with the proviso that when X is fluorine atom, R.sub.3 is not hydrogen, and an intermediate for the preparation thereof, preparation processes of the derivative and anti-tumor agent containing the derivative as an active ingredient.
摘要翻译：本发明提供了下式的5-取代的尿苷衍生物，其中X是F或CF 3，R 1和R 2各自表示-OSi-（R 4）（R 5）（R 6）（其中R 4，R 5和R 6表示C1 -C 10烷基等），OH，其中氨基可被低级烷基或羧基烷基羰基氧基取代的氨基酰氧基，R3是基团-OSi（R4）（R5）（R6），H，OH，氨基酰氧基，其中氨基可以被低级烷基或羧基烷基羰基氧基取代，R 1，R 2和R 3中的至少一个是-OSi-（R 4）（R 5）（R 6）基团，条件是当X是氟原子时， R3不是氢，其制备中间体，衍生物的制备方法和含有该衍生物的抗肿瘤剂作为活性成分。

6. 发明授权

US09611227B2 Antitumor effect potentiator and antitumor agent 有权
公开(公告)号：US09611227B2
公开(公告)日：2017-04-04
申请号：US10548655
申请日：2004-03-11
申请人： Junji Uchida , Koyo Shudo
发明人： Junji Uchida , Koyo Shudo
IPC分类号： A61K31/53 , A61K31/519 , C07D239/553
CPC分类号： A61K31/53 , A61K31/44 , A61K31/513 , A61K31/519 , C07D239/553
摘要： The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect. The antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof. The present invention also provides a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent.

7. 发明申请

US20080306073A1 Antitumor Effect Potentiator, Antitumor Preparation, and Method for Treating Cancer 审中-公开
标题翻译：抗肿瘤效应增强剂，抗肿瘤制剂和治疗癌症的方法
公开(公告)号：US20080306073A1
公开(公告)日：2008-12-11
申请号：US11629185
申请日：2005-06-02
申请人： Katsuhisa Koizumi , Junji Uchida , Teiji Takechi , Mamoru Nukatsuka
发明人： Katsuhisa Koizumi , Junji Uchida , Teiji Takechi , Mamoru Nukatsuka
IPC分类号： A61K31/53 , C07F15/00 , A61P35/00
CPC分类号： A61K45/06 , A61K31/132 , A61K31/44 , A61K31/506 , A61K31/53 , A61K33/24 , A61K2300/00
摘要： An antitumor effect fortifier comprising as an active ingredient an effective amount of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) so as to enhance the antitumor activity of antitumor agent containing a therapeutically effective amount of tegafur, an amount, effective for the enhancement of antitumor effect, of gimeracil and an amount, effective for the suppression of side effects, of oteracil potassium; and a relevant antitumor agent. Further, there is provided a method of therapy for cancer, characterized in that an amount, effective for the enhancement of antitumor effect, of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) is concomitantly administered to a mammal. Still further, there is provided an antitumor agent consisting of a pharmaceutical preparation form composed of at least two separate preparations containing efficacious ingredients consisting of tegafur, gimeracil, oteracil potassium and platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) each alone or in an arbitrary combination, or a pharmaceutical preparation form constituted of a single preparation containing all the efficacious ingredients. Still further, there is provided a relevant kit.
摘要翻译：一种抗肿瘤作用增强剂，其包含有效量的顺式草甘膦（II）顺式草甘膦（1R，2R-二氨基环己烷）作为活性成分，以增强含有治疗有效量的替加氟的抗肿瘤剂的抗肿瘤活性，吉非他赛的抗肿瘤作用的提高和对抑制副作用有效量的奥替卡尔钾; 和相关的抗肿瘤剂。此外，提供了一种癌症治疗方法，其特征在于向哺乳动物伴随施用有效提高抗肿瘤作用的量的铂（II）顺式草酸（1R，2R-二氨基环己烷）的量。另外，提供了由药物制剂形式组成的抗肿瘤药物，该药物制剂形式由至少两个单独的制剂组成，所述制剂含有由替加氟，吉美西尔，邻苯二甲酸钾和顺式草酸二（1R），顺式 - 草酸（1R，2R-二氨基环己烷）组成的有效成分或任意组合，或由含有所有有效成分的单一制剂构成的药物制剂形式。此外，还提供了相关工具包。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式